home / stock / aura / aura articles
BOSTON, May 30, 2024 (GLOBE NEWSWIRE) -- Aura Biosciences, Inc. (NASDAQ:AURA), a clinical-stage biotechnology company developing precision immu...
BOSTON, May 08, 2024 (GLOBE NEWSWIRE) -- Aura Biosciences, Inc. (NASDAQ:AURA), a clinical-stage biotechnology company developing precision immu...
Although U.S. stocks closed lower on Thursday, there were a few notable insider trades. When insiders purchase shares, it indicates their confidenc...
Gainers PaxMedica, Inc. (NASDAQ: PXMD) shares climbed 173.8% to $8.35. PaxMedica announced the publication of its autism spectrum disorder Phase 2...
Gainers Senti Biosciences, Inc. (NASDAQ: SNTI) shares surged 120.8% to $0.6450 in pre-market trading after the company reported a new strategic col...
U.S. stock futures traded lower this morning on Tuesday. Here are some big stocks recording losses in today’s pre-market trading session. Ve...
The most overbought stocks in the health care sector presents an opportunity to go short on these overvalued companies. The RSI is a momentum indic...
News, Short Squeeze, Breakout and More Instantly...
Aura Biosciences Inc. Company Name:
AURA Stock Symbol:
NASDAQ Market:
Aura Biosciences Inc. Website:
(NewsDirect) Aura Energy Ltd (ASX:AEE, AIM:AURA) MD Dave Woodall speaks with Proactive soon after announcing the company has raised A$10 million via a share placement at A$0.185 per share to advance development across the company’s project portfolio. The placement was supported by exis...
(NewsDirect) Aura Energy Limited (ASX: AEE, AIM: AURA) CEO Dave Woodall responds to a recent report that the Industry Committee of the Swedish parliament has voted to reject a number of private members’ motions supporting an immediate lifting of the ban on uranium mining in Sweden. He ...
U.S. Food and Drug Administration (FDA) Grants Fast Track Designation for Belzupacap Sarotalocan (bel-sar) for the Treatment of Choroidal Metastasis, Bel-sar’s Second Ocular Oncology Indication to Receive this Designation Global Phase 3 Trial in Primary Choroidal Melanoma on Track ...